ERS Genomics appoints Eric Rhodes as CEO
Mr. Rhodes joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.
In his most recent role at Horizon Discovery, Mr. Rhodes was responsible for commercializing Horizon’s genome editing technologies as well as overseeing research and development.
Over the course of his career he has held various positions focused on gene editing technologies including the positions of Director Business Development at Sigma-Aldrich and Vice President Business Development & Alliance Management at Sangamo Biosciences where he was responsible for commercializing gene-editing technologies and executed licensing deals with more than 25 major biotechnology and pharmaceutical companies.
Mr. Rhodes holds a degree in microbiology and immunology from the University of California, Berkeley.
He will succeed founder Shaun Foy who has built and led the company since inception. Mr. Foy will become Chairman of the Board of Directors.